Market capitalization | $132.23m |
Enterprise Value | $123.99m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1,270.17 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.16m |
Free Cash Flow (TTM) Free Cash Flow | $-21.84m |
Cash position | $8.64m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
2 Analysts have issued a Actuate Therapeutics forecast:
2 Analysts have issued a Actuate Therapeutics forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -25 -25 |
-
|
EBIT (Operating Income) EBIT | -25 -25 |
-
|
Net Profit | -27 -27 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Head office | United States |
CEO | Daniel Schmitt |
Employees | 10 |
Website | www.actuatetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.